We provide you with 20 years of free, institutional-grade data for IMRX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IMRX. Explore the full financial landscape of IMRX stock.
Total insider purchase within 3 month on this page: $35,993
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Zeskind Benjamin J. | Open Market Purchase | 2,400 | $4.56 | 2026-06-24 | |
| Hall Brett Matthew | Open Market Purchase | 6,035 | $4.15 | 2026-06-16 | |
| Neufeld Leah R | Grant, award...etc | 3,628 | $4.29 | 2026-03-17 | |
| Brakewood Harold Eugene | Open Market Purchase | 5,250 | $4.76 | 2026-01-21 | |
| Schall Thomas J. | Open Market Purchase | 21,645 | $4.67 | 2026-01-20 | |
| Hall Brett Matthew | Open Market Purchase | 2,298 | $4.57 | 2026-01-16 | |
| Neufeld Leah R | Open Market Purchase | 2,626 | $4.15 | 2026-01-15 | |
| Feinberg Peter | Open Market Purchase | 20,000 | $4.35 | 2026-01-14 | |
| Feinberg Peter | Open Market Purchase | 7,500 | $6.67 | 2025-10-07 | |
| Morales Mallory | Open Market Purchase | 300 | $6.39 | 2025-10-02 | |
| Neufeld Leah R | Open Market Purchase | 800 | $6.38 | 2025-10-02 | |
| Bookman Michael | Open Market Purchase | 1,020 | $6.83 | 2025-10-02 | |
| Feinberg Peter | Open Market Purchase | 7,500 | $7.03 | 2025-10-01 | |
| Feinberg Peter | Open Market Purchase | 5,000 | $7.18 | 2025-09-30 | |
| Hall Brett Matthew | Grant, award...etc | 14,880 | $1.43 | 2025-09-17 | |
| Morales Mallory | Grant, award...etc | 14,497 | $1.43 | 2025-09-17 | |
| Neufeld Leah R | Grant, award...etc | 11,815 | $1.43 | 2025-09-17 | |
| HAUSMAN DIANA | Open Market Purchase | 3,000 | $3.62 | 2025-07-07 | |
| HAUSMAN DIANA | Open Market Purchase | 2,500 | $3.6 | 2025-07-07 | |
| Neufeld Leah R | Open Market Purchase | 700 | $3.57 | 2025-07-07 | |
| Zeskind Benjamin J. | Open Market Purchase | 10,000 | $3.38 | 2025-07-03 | |
| Schall Thomas J. | Open Market Purchase | 9,500 | $3.66 | 2025-06-30 | |
| Brakewood Harold Eugene | Open Market Purchase | 1,900 | $2.53 | 2025-06-24 | |
| Hall Brett Matthew | Open Market Purchase | 13,422 | $2.7 | 2025-06-24 | |
| Feinberg Peter | Open Market Purchase | 25,000 | $2.53 | 2025-06-23 | |
| Zeskind Benjamin J. | Open Market Purchase | 21,000 | $2.39 | 2025-06-20 | |
| Schall Thomas J. | Open Market Purchase | 40,485 | $2.21 | 2025-06-18 | |
| Morales Mallory | Grant, award...etc | 4,458 | $1.62 | 2024-09-17 | |
| Cormorant Asset Management, LP | Sale | -400,000 | $3.07 | $1,228,000 | 2024-04-03 |
| Schall Thomas J. | Open Market Purchase | 2,900 | $2.55 | 2024-03-25 | |
| Brakewood Harold Eugene | Open Market Purchase | 3,900 | $2.57 | 2024-03-25 | |
| Feinberg Peter | Open Market Purchase | 25,000 | $2.55 | 2024-03-25 | |
| Morales Mallory | Open Market Purchase | 1,500 | $2.72 | 2024-03-25 | |
| Morales Mallory | Grant, award...etc | 4,344 | $1.62 | 2024-03-25 | |
| Neufeld Leah R | Open Market Purchase | 3,818 | $2.88 | 2024-03-21 | |
| Neufeld Leah R | Grant, award...etc | 6,211 | $1.62 | 2024-03-21 | |
| Hall Brett Matthew | Open Market Purchase | 7,000 | $2.86 | 2024-03-21 | |
| Hall Brett Matthew | Grant, award...etc | 6,211 | $1.62 | 2024-03-21 | |
| Bookman Michael | Grant, award...etc | 1,448 | $1.62 | 2024-03-19 | |
| BERMAN ANN E | Open Market Purchase | 57,965 | $2.13 | 2024-03-19 | |
| Feinberg Peter | Open Market Purchase | 75,000 | $2.31 | 2024-03-19 | |
| Zeskind Benjamin J. | Open Market Purchase | 20,000 | $2.77 | 2024-03-19 | |
| Cormorant Asset Management, LP | Sale | -909,091 | $3.23 | $2,940,909 | 2024-03-18 |
| Zeskind Benjamin J. | Derivatives Exercise | 2,500 | 2022-12-27 |
The information provided in this report about IMRX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Immuneering Corporation(NASDAQ:IMRX) 
Immuneering Corporation provides genetic, genomic, and proteomic data analysis services for pharmaceutical companies to generate biological insights that enhance the clinical and commercial success of medicines. The company was incorporated in 2008 and is based in Cambridge, Massachusetts.
Website: https://immuneering.com/
Founded: 2008
CEO / Co-Founder: Ben Zeskind
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends